2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2789

Enhancing Uveitis Screening Compliance In Juvenile Idiopathic Arthritis Patients
Abstract Number: 1657

Enothelin-1 Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 1114

Entheses Ultrasound In Patients With Ankyosing Spondylitis: A Controlled Study With Healthy Subjects
Abstract Number: 2083

Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis
Abstract Number: 758

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) – Re-Analysis Of The French Vasculitis Study Group Cohort Using Different Disease Definitions and Cluster Analysis
Abstract Number: 759

Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss Syndrome): Comparison Of The Independent French Vasculitis Study Group and Italian–Pisa Patient Cohorts and Cross-Validation Of Cluster Analysis
Abstract Number: 1210

Epicardial Adipose Tissue and Atherosclerosis In Patients With Familial Mediterranean Fever
Abstract Number: 96

Epidemiology and Health Services Use For Osteoarthritis By First Nations People In Alberta, Canada
Abstract Number: 2612

Epidemiology Of Cancer In Systemic Sclerosis. Systematic Review and Meta-Analysis Of Cancer Incidence, Predictors and Mortality
Abstract Number: 2734

Epigenetic Control Of a Gene Regulatory Network Associated With Experimental Autoimmune Arthritis and Rheumatoid Arthritis
Abstract Number: 61

Epigenome-Wide DNA Methylation Study Reveals Hypermethylated Collagen Genes and Suggests a Role for TGFβ in Osteoarthritis
Abstract Number: 2576

Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Abstract Number: 1738

Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Abstract Number: 2335

Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Abstract Number: 2498

ERAP2 Functional Knockout In Humans Does Not Alter ER Stress Or Evidence Of HLA-B27 Misfolding In Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].